• 1
    Gunde E, Blagdon R & Hajek T (2011) White matter hyperintensities: from medical comorbidities to BDs and back. Ann Med 43, 571580.
  • 2
    Konick LC & Friedman L (2001) Meta-analysis of thalamic size in schizophrenia. Biol Psychiatry 49, 2838.
  • 3
    Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM & Bullmore ET (2000) Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157, 1625.
  • 4
    Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, Hays AP & Dwork AJ (2000) Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry 57, 349356.
  • 5
    Thomas AJ, Perry R, Barber R, Kalaria RN & O'Brien JT (2002) Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann N Y Acad Sci 977, 333339.
  • 6
    Gootjes L, Teipel SJ, Zebuhr Y, Schwarz R, Leinsinger G, Scheltens P, Moller HJ & Hampel H (2004) Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 18, 180188.
  • 7
    Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH & Bahn S (2003) Oligodendrocyte dysfunction in schizophrenia and BD. Lancet 362, 798805.
  • 8
    Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, Tsuang MT, Salomon DR, Nurnberger JI Jr & Niculescu AB (2009) Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 14, 156174.
  • 9
    Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 2, 349352.
  • 10
    Klein PS & Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 93, 84558459.
  • 11
    Stambolic V, Ruel L & Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6, 16641668.
  • 12
    Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM & Klein PS (1997) Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 185, 8291.
  • 13
    De Sarno P, Li X & Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 11581164.
  • 14
    Gould TD, Einat H, Bhat R & Manji HK (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7, 387390.
  • 15
    Beaulieu JM (2007) Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int J Neuropsychopharmacol 10, 36.
  • 16
    Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberte C, Khan M, Okamoto K, Chambers JW, Fletcher PJ et al. (2009) Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain 2, 35.
  • 17
    Kimura T, Yamashita S, Nakao S, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N & Takashima A (2008) GSK-3beta is required for memory reconsolidation in adult brain. PLoS One 3, e3540.
  • 18
    Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR & Caron MG (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105, 13331338.
  • 19
    Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, Daneels G, Bouwknecht JA & Steckler T (2006) Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci 26, 90229029.
  • 20
    O'Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT & Klein PS (2011) Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest 121, 37563762.
  • 21
    Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C & Smeraldi E (2004) A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by BD. Neurosci Lett 355, 3740.
  • 22
    Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C & Smeraldi E (2005) Long-term response to lithium salts in BD illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 376, 5155.
  • 23
    Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, Pirovano A, Lorenzi C, Falini A, Colombo C et al. (2013) Lithium and GSK3-beta promoter gene variants influence white matter microstructure in BD. Neuropsychopharmacology 38, 313327.
  • 24
    Zhang K, Yang C, Xu Y, Sun N, Yang H, Liu J, Xu Q & Shen Y (2010) Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J Neural Transm 117, 393401.
  • 25
    Karege F, Perroud N, Schurhoff F, Meary A, Marillier G, Burkhardt S, Ballmann E, Fernandez R, Jamain S, Leboyer M et al. (2010) Association of AKT1 gene variants and protein expression in both schizophrenia and BD. Genes Brain Behav 9, 503511.
  • 26
    Schosser A, Gaysina D, Cohen-Woods S, Chow PC, Martucci L, Craddock N, Farmer A, Korszun A, Gunasinghe C, Gray J et al. (2010) Association of DISC1 and TSNAX genes and affective disorders in the depression case-control (DeCC) and BDaffective case-control (BACCS) studies. Mol Psychiatry 15, 844849.
  • 27
    Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, Sweatt JD, McMahon L, Bartolucci AA, Li X et al. (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35, 17611774.
  • 28
    Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M & Gogos JA (2004) Convergent evidence for impaired AKT1–GSK3beta signaling in schizophrenia. Nat Genet 36, 131137.
  • 29
    Tang H, Shen N, Jin H, Liu D, Miao X & Zhu LQ (2013) GSK-3beta polymorphism discriminates BD and schizophrenia: a systematic meta-analysis. Mol Neurobiol, doi:10.1007/s12035-013-8414-x
  • 30
    Benedetti F, Poletti S, Radaelli D, Bernasconi A, Cavallaro R, Falini A, Lorenzi C, Pirovano A, Dallaspezia S, Locatelli C et al. (2010) Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3-beta activity. Genes Brain Behav 9, 365371.
  • 31
    Woodgett JR (1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9, 24312438.
  • 32
    Leroy K & Brion JP (1999) Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 16, 279293.
  • 33
    Takahashi M, Tomizawa K, Kato R, Sato K, Uchida T, Fujita SC & Imahori K (1994) Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 beta in rat brain. J Neurochem 63, 245255.
  • 34
    Mukai F, Ishiguro K, Sano Y & Fujita SC (2002) Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 81, 10731083.
  • 35
    Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, McLauchlan H, Snider WD, Gordon-Weeks PR & Sutherland C (2010) Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem 115, 974983.
  • 36
    Kennelly PJ & Krebs EG (1991) Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. J Biol Chem 266, 1555515558.
  • 37
    Cross DA, Alessi DR, Cohen P, Andjelkovich M & Hemmings BA (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785789.
  • 38
    Sutherland C, Leighton IA & Cohen P (1993) Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J 296 (Pt 1), 1519.
  • 39
    Thomas GM, Frame S, Goedert M, Nathke I, Polakis P & Cohen P (1999) A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 458, 247251.
  • 40
    Ding VW, Chen RH & McCormick F (2000) Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 275, 3247532481.
  • 41
    Cole A, Frame S & Cohen P (2004) Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 377, 249255.
  • 42
    Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N & Cleghon V (2006) A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 24, 627633.
  • 43
    Cole AR (2012) GSK3 as a sensor determining cell fate in the brain. Front Mol Neurosci 5, 4.
  • 44
    Sutherland C (2011) What are the bona fide GSK3 substrates? Int J Alzheimers Dis 2011, 505607.
  • 45
    Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, St Clair DM, Muir WJ, Blackwood DH et al. (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 9, 14151423.
  • 46
    Thomson PA, Parla JS, McRae AF, Kramer M, Ramakrishnan K, Yao J, Soares DC, McCarthy S, Morris SW, Cardone L et al. (2013) 708 Common and 2010 rare DISC1 locus variants identified in 1542 subjects: analysis for association with psychiatric disorder and cognitive traits. Mol Psychiatry doi:10.1038/mp.2013.68.
  • 47
    Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK et al. (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136, 10171031.
  • 48
    Singh KK, De Rienzo G, Drane L, Mao Y, Flood Z, Madison J, Ferreira M, Bergen S, King C, Sklar P et al. (2011) Common DISC1 polymorphisms disrupt Wnt/GSK3beta signaling and brain development. Neuron 72, 545558.
  • 49
    Law AJ, Wang Y, Sei Y, O'Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W, Thomas CJ, Vakkalanka R et al. (2012) Neuregulin 1–ErbB4–PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci USA 109, 1216512170.
  • 50
    Li X & Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35, 21432154.
  • 51
    Kang UG, Roh MS, Jung JR, Shin SY, Lee YH, Park JB & Kim YS (2004) Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 28, 4144.
  • 52
    Li X, Zhu W, Roh MS, Friedman AB, Rosborough K & Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29, 14261431.
  • 53
    Cowen DS, Johnson-Farley NN & Travkina T (2005) 5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons. J Neurochem 93, 910917.
  • 54
    Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR & Caron MG (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 101, 50995104.
  • 55
    Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR & Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261273.
  • 56
    Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR & Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125136.
  • 57
    Lamont EW, Legault-Coutu D, Cermakian N & Boivin DB (2007) The role of circadian clock genes in mental disorders. Dialogues Clin Neurosci 9, 333342.
  • 58
    Geller B, Williams M, Zimerman B, Frazier J, Beringer L & Warner KL (1998) Prepubertal and early adolescent bipolarity differentiate from ADHD by manic symptoms, grandiose delusions, ultra-rapid or ultradian cycling. J Affect Disord 51, 8191.
  • 59
    Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353, 12091223.
  • 60
    Cohrs S (2008) Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 22, 939962.
  • 61
    Manoach DS & Stickgold R (2009) Does abnormal sleep impair memory consolidation in schizophrenia? Front Hum Neurosci 3, 21.
  • 62
    Sahar S, Zocchi L, Kinoshita C, Borrelli E & Sassone-Corsi P (2010) Regulation of BMAL1 protein stability and circadian function by GSK3beta-mediated phosphorylation. PLoS One 5, e8561.
  • 63
    Harada Y, Sakai M, Kurabayashi N, Hirota T & Fukada Y (2005) Ser-557-phosphorylated mCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3 beta. J Biol Chem 280, 3171431721.
  • 64
    Spengler ML, Kuropatwinski KK, Schumer M & Antoch MP (2009) A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation. Cell Cycle 8, 41384146.
  • 65
    Ko HW, Kim EY, Chiu J, Vanselow JT, Kramer A & Edery I (2010) A hierarchical phosphorylation cascade that regulates the timing of PERIOD nuclear entry reveals novel roles for proline-directed kinases and GSK-3beta/SGG in circadian clocks. J Neurosci 30, 1266412675.
  • 66
    Martinek S, Inonog S, Manoukian AS & Young MW (2001) A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105, 769779.
  • 67
    Yin L, Wang J, Klein PS & Lazar MA (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311, 10021005.
  • 68
    Frame S & Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359, 116.
  • 69
    Iwahana E, Akiyama M, Miyakawa K, Uchida A, Kasahara J, Fukunaga K, Hamada T & Shibata S (2004) Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 protein expression in the mouse suprachiasmatic nuclei. Eur J Neurosci 19, 22812287.
  • 70
    Iitaka C, Miyazaki K, Akaike T & Ishida N (2005) A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J Biol Chem 280, 2939729402.
  • 71
    Paul JR, Johnson RL, Jope RS & Gamble KL (2012) Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3. Neuroscience 226, 19.
  • 72
    Hirota T, Lewis WG, Liu AC, Lee JW, Schultz PG & Kay SA (2008) A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3beta. Proc Natl Acad Sci USA 105, 2074620751.
  • 73
    Li J, Lu WQ, Beesley S, Loudon AS & Meng QJ (2012) Lithium impacts on the amplitude and period of the molecular circadian clockwork. PLoS One 7, e33292.
  • 74
    Engelmann W (1987) Effects of lithium salts on circadian rhythms. In Chronobiology and Psychiatric Disorders (Halaris, A ed.), pp. 263289. Elsevier, Amsterdam.
  • 75
    Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P & Smith A (2008) The ground state of embryonic stem cell self-renewal. Nature 453, 519523.
  • 76
    Sato N, Meijer L, Skaltsounis L, Greengard P & Brivanlou AH (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 10, 5563.
  • 77
    Doble BW, Patel S, Wood GA, Kockeritz LK & Woodgett JR (2007) Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 12, 957971.
  • 78
    Kim WY, Wang X, Wu Y, Doble BW, Patel S, Woodgett JR & Snider WD (2009) GSK-3 is a master regulator of neural progenitor homeostasis. Nat Neurosci 12, 13901397.
  • 79
    Eom TY & Jope RS (2009) Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation. Biol Psychiatry 66, 494502.
  • 80
    Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A & Lesch KP (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 11, 514522.
  • 81
    Maciag D, Hughes J, O'Dwyer G, Pride Y, Stockmeier CA, Sanacora G & Rajkowska G (2010) Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 67, 465470.
  • 82
    Higashi M, Maruta N, Bernstein A, Ikenaka K & Hitoshi S (2008) Mood stabilizing drugs expand the neural stem cell pool in the adult brain through activation of notch signaling. Stem Cells 26, 17581767.
  • 83
    Wexler EM, Geschwind DH & Palmer TD (2008) Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry 13, 285292.
  • 84
    Cole AR (2013) Regulation of cell fate in the brain by GSK3. In Trends in Cell Signalling Pathways in Neuronal Fate Decision (Wislet-Gendebien S, ed.), pp. 153177. InTech Publishing, Rijeka, Croatia.
  • 85
    Kim WY & Snider WD (2011) Functions of GSK-3 signaling in development of the nervous system. Front Mol Neurosci 4, 44.
  • 86
    Moberg KH, Mukherjee A, Veraksa A, Artavanis-Tsakonas S & Hariharan IK (2004) The Drosophila F box protein archipelago regulates dMyc protein levels in vivo. Curr Biol 14, 965974.
  • 87
    Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN & Clurman BE (2004) The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA 101, 90859090.
  • 88
    Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K & Nakayama KI (2004) Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 23, 21162125.
  • 89
    Wei W, Jin J, Schlisio S, Harper JW & Kaelin WG Jr (2005) The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 2533.
  • 90
    Liu N, Li H, Li S, Shen M, Xiao N, Chen Y, Wang Y, Wang W, Wang R, Wang Q et al. (2010) The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem 285, 1885818867.
  • 91
    Zhao D, Zheng HQ, Zhou Z & Chen C (2010) The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res 70, 47284738.
  • 92
    Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE & Roberts JM (2003) Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12, 381392.
  • 93
    Jia J, Amanai K, Wang G, Tang J, Wang B & Jiang J (2002) Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416, 548552.
  • 94
    Price MA & Kalderon D (2002) Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1. Cell 108, 823835.
  • 95
    Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M & Hung MC (2004) Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial–mesenchymal transition. Nat Cell Biol 6, 931940.
  • 96
    Cartwright P, McLean C, Sheppard A, Rivett D, Jones K & Dalton S (2005) LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132, 885896.
  • 97
    Yanagi M, Hashimoto T, Kitamura N, Fukutake M, Komure O, Nishiguchi N, Kawamata T, Maeda K & Shirakawa O (2008) Expression of Kruppel-like factor 5 gene in human brain and association of the gene with the susceptibility to schizophrenia. Schizophr Res 100, 291301.
  • 98
    Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F & Kennedy JL (2002) The brain-derived neurotrophic factor gene confers susceptibility to BD: evidence from a family-based association study. Am J Hum Genet 71, 651655.
  • 99
    Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, Schulze TG, Deschner M, Schmal C, Hofels S et al. (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58, 307314.
  • 100
    Pezawas L, Verchinski BA, Mattay VS, Callicott JH, Kolachana BS, Straub RE, Egan MF, Meyer-Lindenberg A & Weinberger DR (2004) The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 24, 1009910102.
  • 101
    Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA & Pandey GN (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60, 804815.
  • 102
    Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P et al. (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43, 247254.
  • 103
    Sen S, Duman R & Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64, 527532.
  • 104
    Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S et al. (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54, 7075.
  • 105
    Brunoni AR, Lopes M & Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11, 11691180.
  • 106
    Nibuya M, Morinobu S & Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15, 75397547.
  • 107
    Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R et al. (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J Neurosci 23, 349357.
  • 108
    Yasuda S, Liang MH, Marinova Z, Yahyavi A & Chuang DM (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14, 5159.
  • 109
    Fukumoto T, Morinobu S, Okamoto Y, Kagaya A & Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology 158, 100106.
  • 110
    Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H & Laske C (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 16, 649656.
  • 111
    Siuciak JA, Lewis DR, Wiegand SJ & Lindsay RM (1997) Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav 56, 131137.
  • 112
    Horch HW & Katz LC (2002) BDNF release from single cells elicits local dendritic growth in nearby neurons. Nat Neurosci 5, 11771184.
  • 113
    Chen F, Madsen TM, Wegener G & Nyengaard JR (2010) Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus 20, 13761384.
  • 114
    Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ & Greenberg ME (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709726.
  • 115
    Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ & Andrisani OM (1994) A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem 269, 3218732193.
  • 116
    Grimes CA & Jope RS (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78, 12191232.
  • 117
    Young LT, Bezchlibnyk YB, Chen B, Wang JF & MacQueen GM (2004) Amygdala cyclic adenosine monophosphate response element binding protein phosphorylation in patients with mood disorders: effects of diagnosis, suicide, and drug treatment. Biol Psychiatry 55, 570577.
  • 118
    Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ & Xu M (2002) c-fos regulates neuronal excitability and survival. Nat Genet 30, 416420.
  • 119
    Mai L, Jope RS & Li X (2002) BDNF-mediated signal transduction is modulated by GSK3beta and mood stabilizing agents. J Neurochem 82, 7583.
  • 120
    Hernandez F, Langa E, Cuadros R, Avila J & Villanueva N (2010) Regulation of GSK3 isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 344, 211215.
  • 121
    Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, Karayiorgou M & Tonegawa S (2003) Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 100, 89938998.
  • 122
    Peineau S, Nicolas CS, Bortolotto ZA, Bhat RV, Ryves WJ, Harwood AJ, Dournaud P, Fitzjohn SM & Collingridge GL (2009) A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases. Mol Brain 2, 22.
  • 123
    Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, Lu J, Lo E, Wu D, Saule E, Bouschet T et al. (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703717.
  • 124
    Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T et al. (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 8186.
  • 125
    Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, Wang Q, Chen JG & Wang JZ (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27, 1221112220.
  • 126
    Li YC, Xi D, Roman J, Huang YQ & Gao WJ (2009) Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29, 1555115563.
  • 127
    Zhu LQ, Liu D, Hu J, Cheng J, Wang SH, Wang Q, Wang F, Chen JG & Wang JZ (2010) GSK-3 beta inhibits presynaptic vesicle exocytosis by phosphorylating P/Q-type calcium channel and interrupting SNARE complex formation. J Neurosci 30, 36243633.
  • 128
    Clayton EL, Sue N, Smillie KJ, O'Leary T, Bache N, Cheung G, Cole AR, Wyllie DJ, Sutherland C, Robinson PJ et al. (2010) Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. Nat Neurosci 13, 845851.
  • 129
    Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18, 2529.
  • 130
    Borsotto M, Cavarec L, Bouillot M, Romey G, Macciardi F, Delaye A, Nasroune M, Bastucci M, Sambucy JL, Luan JJ et al. (2007) PP2A-Bgamma subunit and KCNQ2 K+ channels in BD. Pharmacogenomics J 7, 123132.
  • 131
    Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR & Khanna R (2009) An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J Biol Chem 284, 3137531390.
  • 132
    Chi XX, Schmutzler BS, Brittain JM, Wang Y, Hingtgen CM, Nicol GD & Khanna R (2009) Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J Cell Sci 122, 43514362.
  • 133
    Nishimura T, Fukata Y, Kato K, Yamaguchi T, Matsuura Y, Kamiguchi H & Kaibuchi K (2003) CRMP-2 regulates polarized Numb-mediated endocytosis for axon growth. Nat Cell Biol 5, 819826.
  • 134
    Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN & Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279, 5017650180.
  • 135
    Cole AR, Causeret F, Yadirgi G, Hastie CJ, McLauchlan H, McManus EJ, Hernandez F, Eickholt BJ, Nikolic M & Sutherland C (2006) Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 281, 1659116598.
  • 136
    Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A & Kaibuchi K (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120, 137149.
  • 137
    Uchida Y, Ohshima T, Sasaki Y, Suzuki H, Yanai S, Yamashita N, Nakamura F, Takei K, Ihara Y, Mikoshiba K et al. (2005) Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Genes Cells 10, 165179.
  • 138
    Brown M, Jacobs T, Eickholt B, Ferrari G, Teo M, Monfries C, Qi RZ, Leung T, Lim L & Hall C (2004) Alpha2-chimaerin, cyclin-dependent kinase 5/p35, and its target collapsin response mediator protein-2 are essential components in semaphorin 3A-induced growth-cone collapse. J Neurosci 24, 89949004.
  • 139
    Brittain JM, Wang Y, Eruvwetere O & Khanna R (2012) Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett 586, 38133818.
  • 140
    Nakata K, Ujike H, Sakai A, Takaki M, Imamura T, Tanaka Y & Kuroda S (2003) The human dihydropyrimidinase-related protein 2 gene on chromosome 8p21 is associated with paranoid-type schizophrenia. Biol Psychiatry 53, 571576.
  • 141
    Nakata K, Ujike H, Tanaka Y, Takaki M, Sakai A, Nomura A, Katsu T, Uchida N, Imamura T, Fujiwara Y et al. (2003) No association between the dihydropyrimidinase-related protein 2 (DRP-2) gene and BD in humans. Neurosci Lett 349, 171174.
  • 142
    Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL et al. (2005) BDI disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 77, 918936.
  • 143
    Martins-De-Souza D, Dias-Neto E, Schmitt A, Falkai P, Gormanns P, Maccarrone G, Turck CW & Gattaz WF (2010) Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatry 11, 110120.
  • 144
    Hanger DP, Hughes K, Woodgett JR, Brion JP & Anderton BH (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147, 5862.
  • 145
    Goold RG, Owen R & Gordon-Weeks PR (1999) Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones. J Cell Sci 112 (Pt 19), 33733384.
  • 146
    Farghaian H, Turnley AM, Sutherland C & Cole AR (2011) Bioinformatic prediction and confirmation of beta-adducin as a novel substrate of glycogen synthase kinase 3. J Biol Chem 286, 2527425283.
  • 147
    Wittmann T & Waterman-Storer CM (2005) Spatial regulation of CLASP affinity for microtubules by Rac1 and GSK3beta in migrating epithelial cells. J Cell Biol 169, 929939.
  • 148
    Hergovich A, Lisztwan J, Thoma CR, Wirbelauer C, Barry RE & Krek W (2006) Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Mol Cell Biol 26, 57845796.
  • 149
    Chen P, Gu Z, Liu W & Yan Z (2007) Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons. Mol Pharmacol 72, 4051.
  • 150
    Nishimoto T, Kihara T, Akaike A, Niidome T & Sugimoto H (2009) AMPA reduces surface expression of NR1 through regulation of GSK3beta. NeuroReport 20, 161165.
  • 151
    Wei J, Liu W & Yan Z (2010) Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3. J Biol Chem 285, 2636926376.
  • 152
    Yanagita T, Maruta T, Nemoto T, Uezono Y, Matsuo K, Satoh S, Yoshikawa N, Kanai T, Kobayashi H & Wada A (2009) Chronic lithium treatment up-regulates cell surface Na(V)1.7 sodium channels via inhibition of glycogen synthase kinase-3 in adrenal chromaffin cells: enhancement of Na(+) influx, Ca(2+) influx and catecholamine secretion after lithium withdrawal. Neuropharmacology 57, 311321.
  • 153
    Chen L, Salinas GD & Li X (2009) Regulation of serotonin 1B receptor by glycogen synthase kinase-3. Mol Pharmacol 76, 11501161.
  • 154
    Chen L, Zhou W, Chen PC, Gaisina I, Yang S & Li X (2011) Glycogen synthase kinase-3beta is a functional modulator of serotonin-1B receptors. Mol Pharmacol 79, 974986.
  • 155
    Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST, Einat H & Manji HK (2004) Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24, 65786589.
  • 156
    Roberts MS, Woods AJ, Dale TC, Van Der Sluijs P & Norman JC (2004) Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol 24, 15051515.
  • 157
    Glessner JT, Reilly MP, Kim CE, Takahashi N, Albano A, Hou C, Bradfield JP, Zhang H, Sleiman PM, Flory JH et al. (2010) Strong synaptic transmission impact by copy number variations in schizophrenia. Proc Natl Acad Sci USA 107, 1058410589.
  • 158
    Moskvina V, Craddock N, Holmans P, Nikolov I, Pahwa JS, Green E, Owen MJ & O'Donovan MC (2009) Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and BD and for overlap in genetic risk. Mol Psychiatry 14, 252260.
  • 159
    Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK et al. (2008) Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in BD. Nat Genet 40, 10561058.
  • 160
    Nyegaard M, Demontis D, Foldager L, Hedemand A, Flint TJ, Sorensen KM, Andersen PS, Nordentoft M, Werge T, Pedersen CB et al. (2010) CACNA1C (rs1006737) is associated with schizophrenia. Mol Psychiatry 15, 119121.
  • 161
    Kelmendi B, Holsbach-Beltrame M, McIntosh AM, Hilt L, George ED, Kitchen RR, Carlyle BC, Pittenger C, Coric V, Nolen-Hoeksema S et al. (2011) Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neurosci Lett 496, 195199.
  • 162
    Petryshen TL, Middleton FA, Tahl AR, Rockwell GN, Purcell S, Aldinger KA, Kirby A, Morley CP, McGann L, Gentile KL et al. (1057) (2005) Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Mol Psychiatry 10, 10741088, 1057.
  • 163
    Craddock N, Jones L, Jones IR, Kirov G, Green EK, Grozeva D, Moskvina V, Nikolov I, Hamshere ML, Vukcevic D et al. (2010) Strong genetic evidence for a selective influence of GABAA receptors on a component of the BD phenotype. Mol Psychiatry 15, 146153.
  • 164
    Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ et al. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460, 753757.